Clinical Trial Update: Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). [Phase 3]

View source ↗

Summary

Phase 3 trial update on long-term efficacy and safety of tozorakimab in COPD patients with a history of exacerbations (PROSPERO).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Tozorakimab (tozorakimab)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED